These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 12239812)
1. [Protein C--a new opening in the treatment of sepsis syndrome]. Petäjä J; Heikinheimo M Duodecim; 2002; 118(12):1217-9. PubMed ID: 12239812 [No Abstract] [Full Text] [Related]
2. [PROWESS--milestone in lowering sepsis mortality]. Reinhart K Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016 [No Abstract] [Full Text] [Related]
3. Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis. Dellinger RP Crit Care; 2006 Feb; 10(1):114. PubMed ID: 16542472 [TBL] [Abstract][Full Text] [Related]
4. Breakthrough found in treatment of severe sepsis. Clin Resour Manag; 2001 Jul; 2(7):107-9. PubMed ID: 11482248 [TBL] [Abstract][Full Text] [Related]
5. Severe sepsis. Bernard G Am J Surg; 2002 Dec; 184(6A Suppl):S3-4. PubMed ID: 12521611 [No Abstract] [Full Text] [Related]
6. Recombinant human activated protein C for severe sepsis. O'Connor PE N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463024 [No Abstract] [Full Text] [Related]
7. Best evidence in anesthetic practice: prevention: recombinant human activated protein C reduces mortality in severe sepsis. Butler R; Laufer B Can J Anaesth; 2002 Feb; 49(2):207-9. PubMed ID: 11823403 [No Abstract] [Full Text] [Related]
8. Recombinant human activated protein C for severe sepsis. Ott A; Verbrugh HA N Engl J Med; 2001 Jul; 345(3):220; author reply 220-1. PubMed ID: 11463023 [No Abstract] [Full Text] [Related]
9. Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside. Maki DG Am J Surg; 2002 Dec; 184(6A Suppl):S47-50. PubMed ID: 12521617 [No Abstract] [Full Text] [Related]
10. Drotrecogin alfa (activated) for severe sepsis. Maglio D Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766 [No Abstract] [Full Text] [Related]
11. Recombinant human activated protein C for severe sepsis. Kapur S; Kupfer Y; Tessler S N Engl J Med; 2001 Jul; 345(3):219-20; author reply 220-1. PubMed ID: 11463021 [No Abstract] [Full Text] [Related]
12. Recombinant human activated protein C for severe sepsis. Greisman SE; Johnston CA; Gosnell MS N Engl J Med; 2001 Jul; 345(3):219; author reply 220-1. PubMed ID: 11463022 [No Abstract] [Full Text] [Related]
13. Is industry guiding the sepsis guidelines? A perspective. Durbin CG Crit Care Med; 2007 Mar; 35(3):689-91. PubMed ID: 17255867 [No Abstract] [Full Text] [Related]
14. Drotrecogin Alfa (Activated): From Bench to Practical Use at the Bedside. Proceedings of meetings of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Clinical Evaluation Committee. Am J Surg; 2002 Dec; 184(6A Suppl):1S-49S. PubMed ID: 12521610 [No Abstract] [Full Text] [Related]
15. [A new drug which saves lives. Sepsis: chaos in the body--recent aspects of pathophysiology and therapy]. Haas I Krankenpfl J; 2002; 40(10-12):310-4. PubMed ID: 12600015 [No Abstract] [Full Text] [Related]
16. Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist. Powers J; Jacobi J Clin Nurse Spec; 2003 May; 17(3):128-30. PubMed ID: 12792186 [No Abstract] [Full Text] [Related]
17. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis. Dhainaut JF Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612 [No Abstract] [Full Text] [Related]
18. [Endogenous anticoagulant therapy for sepsis. Success and failure]. Wiedermann CJ Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117 [TBL] [Abstract][Full Text] [Related]